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Prevalence, determinants, and characteristics of extemporaneous compounding
in Jordanian pharmacies
Abstract
Background:
Pharmaceutical compounding is an essential component in pharmacy practice allowing pharmacists to
provide dosage forms or strengths that are commercially unavailable. Medications compounded for
patient-specific needs contribute to personalized medicine. Extemporaneous compounding provided by
pharmacies overcomes the market shortage of these therapeutic products. The aim of this study is to
investigate and characterize the prevalence, characteristics, and determinants of extemporaneous
compounding in Jordanian pharmacies.
Methods:
This study was based on a cross-sectional questionnaire and included 431 randomly selected
pharmacies in the twelve governorates of the country. Data were collected via face to face interviews of
pharmacists who voluntarily and verbally responded to the questions.
Results:
Results revealed that 223 (51.7%) of the surveyed pharmacies practiced extemporaneous compounding.
The main reason for not providing extemporaneous compounding services was lack of prescription
orders for compounded preparations (53.8%). The second reason was lack of the equipment and supplies
necessary for compounding (24.4%). Extemporaneous compounding prescriptions were mainly issued by
dermatologists (98.2%); dermatological indication was the most common of all extemporaneous
compounded prescriptions. The main reason for requesting compounded medications was the lack of a
commercially available product (87.9%). The vast majority of the compounded dosage forms were
creams (99.6) and ointments (91.5), followed by solutions (23.3%). Only 5 (2.2%) of the studied
compounding pharmacies prepared sterile products. The major sources for compounding protocols were
the physician order (94.2%), and ‘in-house’ protocols (44.8%). However, the main resource for estimating
compounded medications expiration date was information based on pharmacist’s experience (57.8%) and
the physician’s order (53.4%).
Conclusions:
Extemporaneous compounding is a common element of pharmaceutical care. Topical preparations are
the most commonly compounded products. Finding from this study suggest that there is a need for
standardizing the compounded product formularies, product quality testing, and improving the
consistency in estimation of an expiration date of compounded products.
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Abstract
Background: Pharmaceutical compounding is an essential component in pharmacy practice allowing pharmacists
to provide dosage forms or strengths that are commercially unavailable. Medications compounded for patientspecific needs contribute to personalized medicine. Extemporaneous compounding provided by pharmacies
overcomes the market shortage of these therapeutic products. The aim of this study is to investigate and
characterize the prevalence, characteristics, and determinants of extemporaneous compounding in Jordanian
pharmacies.
Methods: This study was based on a cross-sectional questionnaire and included 431 randomly selected pharmacies
in the twelve governorates of the country. Data were collected via face to face interviews of pharmacists who
voluntarily and verbally responded to the questions.
Results: Results revealed that 223 (51.7%) of the surveyed pharmacies practiced extemporaneous compounding.
The main reason for not providing extemporaneous compounding services was lack of prescription orders for
compounded preparations (53.8%). The second reason was lack of the equipment and supplies necessary for
compounding (24.4%). Extemporaneous compounding prescriptions were mainly issued by dermatologists (98.2%);
dermatological indication was the most common of all extemporaneous compounded prescriptions. The main
reason for requesting compounded medications was the lack of a commercially available product (87.9%). The vast
majority of the compounded dosage forms were creams (99.6) and ointments (91.5), followed by solutions (23.3%).
Only 5 (2.2%) of the studied compounding pharmacies prepared sterile products. The major sources for
compounding protocols were the physician order (94.2%), and ‘in-house’ protocols (44.8%). However, the main
resource for estimating compounded medications expiration date was information based on pharmacist’s
experience (57.8%) and the physician’s order (53.4%).
Conclusions: Extemporaneous compounding is a common element of pharmaceutical care. Topical preparations
are the most commonly compounded products. Finding from this study suggest that there is a need for
standardizing the compounded product formularies, product quality testing, and improving the consistency in
estimation of an expiration date of compounded products.
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Background
Extemporaneous compounding refers to the practice
of the preparation of a therapeutic product by mixing
and combining pharmaceuticals agents for an individual patient in response to an identified need [1]. Extemporaneous
compounding was traditionally used to fill most of the prescription orders submitted to pharmacists until the advent of
pharmaceutical industry in the second half of the nineteenth
century [2].
Nevertheless, extemporaneous compounding is still a relevant pharmaceutical service provided by many pharmacies
worldwide [3–8]. The continued need for extemporaneous
compounding in the age of pharmaceutical manufacturing is
driven by the individualized patient care focusing on the
therapeutic needs of patients with rare diseases [9], pediatric
patients [10–12] and patients with requirements for special
dosage forms, individualized dosing or active ingredients
combination that are not provided commercially [1, 2, 6].
Moreover, from a professional point of view, compounding
is a very unique attribute of a pharmacy practice that reflects
on the professional status of pharmacists’ provision for
patient-specific healthcare needs [5].
Application of quality standards in extemporaneous
compounding is still a major concern for regulatory agencies since poor quality of compounding practices can result in life-threatening contamination or in products that
don’t possess the required strength, quality, and purity
[13]. In the United States, the process of extemporaneous
compounding of sterile and nonsterile preparations in
pharmacies, which are under the authority of the state
boards of pharmacy, has been regulated, to varying extents, by the United States Pharmacopeia (USP) chapters
<795> Pharmaceutical Compounding – Nonsterile Preparations and <797> Pharmaceutical Compounding – Sterile
Preparations [14]. However, the safety and efficacy of
compounded products are not clinically evaluated [15].
Extemporaneous compounding is performed in a considerable number of Jordanian pharmacies; however, the
practice has never been assessed and characterized by any
previous study. This study was designed to investigate the
prevalence, characteristics, and determinants of extemporaneous compounding in Jordan. The findings from this
study will improve the understanding of current extemporaneous compounding practices and provide information to guide efforts on developing the regulatory
framework, educational curricula, and professional training needed to ensure safety and quality of compounded
products and pharmaceutical care of patients.
Methods
Data collection

Data for this project were collected using a cross-sectional
descriptive questionnaire. The questionnaire was constructed based on information collected from intense
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review of published relevant literature [1, 6, 15, 16]. A 5section questionnaire was developed to obtain data from
pharmacies to assess prevalence, frequency, and determinants of extemporaneous compounding (Additional file
1). The first section had thirteen items related to demographics of pharmacies and pharmacists’ and descriptive
data including: pharmacy name, address, and type,
pharmacist gender, age, qualifications, and position, and
the number of the pharmacy staff members; training provided by the pharmacy, and provision of compounding
services. The second section described prescriptions characteristics and reasons for compounding. The third section assessed the indications, types, and dosage forms of
compounded medications. The fourth section asked about
tools and equipment available for compounding. The fifth
section assessed the formulation properties; resources for
compounding protocols and estimation of expiration date
for compounded medications.
Administration of this questionnaire was based on a
personal interview with the pharmacist on duty; the data
collector asked the pharmacist the questions and filled
the questionnaire. Four senior pharmacy students performed the interviews with the participants. All interviewers were trained by the principal investigator (PI)
and two of the co-investigators. The training focused on
communication skills with the pharmacy staff and on
correct administration of the questionnaire. Moreover,
the questionnaire was supplemented with a protocol
with instructions. The interviewers were instructed to
contact the PI in case of any uncertainty to ensure
consistency in administration of the questionnaire.
The questionnaire was distributed to pharmacists from
431 randomly selected community and hospital pharmacies located in cities in the 12 governorates of Jordan.
There were no exclusion criteria. The population frame
was obtained as a list of all operating pharmacies (community and hospital) in the twelve governorates of
Jordan. The list was provided by the Jordan Pharmacy
Syndicate. Data were collected in February, 2018. Participating pharmacists were requested to sign an informed
consent before responding to the questionnaire.
The data collection tool was evaluated by an expert in
the field of pharmacy practice and piloting. A pilot test
of the 26-item questionnaire was conducted in 30 pharmacies that were randomly-selected. The results from
the pilot study were evaluated and used to modify the
data collection tool before starting the main data collection period. Statistical confirmation of validity and reliability was achieved through the calculation of
Cronbach’ Alpha value which was found to be 0.907 indicating consistency of the tool. Sampling adequacy was
also confirmed using Principal Components Analysis
(PCA) with Kaiser-Meyer-Olkin (KMO) equal to 0.841
and a significant Bartlett’s Test (p = 0.000).
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Table 1 Demographic characteristics of pharmacies
participating in the Study

Table 1 Demographic characteristics of pharmacies
participating in the Study (Continued)

Characteristic

Number (%)

Pharmacies invited to participate in study

444(100)

Pharmacies that participated in study

431(97.1)

Pharmacy Type
Hospital

23 (5.3)

Community

408 (94.7)

Chain

114 (27.9)

Independent

294 (72.1)

Female

235 (54.5)

Male

196 (45.5)

Pharmacist Age, years
220 (51.0)

30–40

105 (24.4)

40 +

106 (24.6)

Personnel
Pharmacist

403 (93.5)

Registered Pharmacy Assistant

28 (6.5)

Pharmacists’ Qualification
Doctorate Degree

3 (0.7)

Master Degree

15 (3.5)

Bachelor Degree

375 (87)

Diploma Degree

38 (8.8)

Number of Pharmacists per Pharmacy
1

84 (19.5)

2

216 (50.1)

3

78 (18.1)

4

29 (6.7)

≥5

24 (5.6)

Number of Assistants per Pharmacy
0

236 (54.8)

1

130 (30.2)

2

54 (12.5)

≥3

11 (2.5)

Number of Personnel per Pharmacy
0

223 (51.7)

1

171 (39.7)

2

25 (5.8)

≥3

12 (2.8)

Plan to Start Compounding Services (N = 208)
Yes

66 (31.7)

No

142 (68.3)

Training on Compounding Provided in Pharmacy
For Pharmacists

Characteristic
For Registered Assistants

Number (%)
109 (25.3)

To minimize social desirability bias, assurance was
given to interviewees that discussions would be confidential and their responses would be anonymized. Collected data was stored with the corresponding author
and further analysis was done anonymously.
Statistical evaluation

Pharmacist Gender (N = 431)

23–30
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235 (54.5)

The sample size was calculated using compounded medications prevalence values (P) described in Buurma et al.
[16] and Zaid et al. [6], Zα = 1.96, and d = 0.05. This calculation showed that 50 to 308 pharmacies were required to ensure reliable sample size to describe the
compounded medication frequency and characteristics.
Categorical data were presented as frequency and percentages, while continuous data were presented as median and interquartile ranges.
Bivariate analysis was used to test the differences
among the variables that affect the compounding of extemporaneous drug preparations. Chi-square or MannWhitney tests were used to detect differences between
different determinants. Logistic regression was used to
evaluate the strength of association of factors that significantly determine the characteristics of compounding
in the bivariate analysis. All hypothesis testing was twosided. A P-value of < 0.05 was considered significant.
Data analysis was performed using SPSS® 23.0 (IBM,
Chicago, IL).

Results
The data collection team approached 444 community
and hospital pharmacies. Invitation to participate in this
study was accepted by 431 (97.1%) pharmacies. A total
of 408 community pharmacies (18.1% of all Jordanian
community pharmacies [17]) and 23 hospital pharmacies
(21.7% of all Jordanian hospitals [18]) provided responses to the study questionnaire.
Demographics and basic characteristics of the participating pharmacies are presented in Table 1 and Table 2.
The vast majority of the participating pharmacies were
community pharmacies that were not part of a chain,
and half of these pharmacies were run by two pharmacists. The pharmacy staff has one pharmacy assistant
and one staff personnel in 130 (30.2%) and 171 (39.7%)
of pharmacies, respectively. More than 400 (93%) of the
interviewed staff were pharmacists, and 375 (87%) of
them had the bachelor university degree, while the rest
of pharmacists have a master or PhD degree as shown in
Table 2. the median daily number of prescription
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received by pharmacies (with or without compounding
orders) was 20 (IQR:10–30) while the median daily
number of prescriptions containing at least one compounding order was 1.5 (IQR: 1–4.8). Table 2 also shows
factors that the pharmacy staff consider in deciding
whether to compound prescribed medication. The main
reason for requesting compounded medication is the unavailability of the required medication (196, 87.9%),
followed by lack of the needed dose among commercially available products (152, 68.2%). The main reason
for not performing compounding was the absence of
compounding orders in (232, 53.8%). The lack of

Page 4 of 9

equipment, tools, facilities, and resources required for
compounding of prescriptions was reported by 24.4% of
pharmacies as a reason for not compounding.
Table 3 shows data comparing pharmacies that perform compounding and pharmacies that do not compound. Being an independently-owned or chain
pharmacy had no effect on its practice of compounding.
The presence of a pharmacy technician (two-year diploma) as a part of the pharmacy staff did not affect the
compounding practice of pharmacies. Significant differences were observed between hospital and community
pharmacies in terms of compounding; community

Table 2 Characteristics of Participating Pharmacies Performing Extemporaneous Compounding
Parameter

N (%)

Median (IQR)

Perform Compounding
Yes

223 (51.7)

Hospital

3(1.3)

Community

220 (98.7)

Yes

208 (48.3)

Hospital

20 (9.6)

Community

188 (90.4)

Average Number of Total Prescriptions/day (N=382)

20 (10–30)

Average Number of Prescriptions per day for Compounded Orders* (N=16)a

1.5 (1–4.8)
a

Average Number of Prescriptions per week for Compounding Orders* (N=42)

2 (1–3)

Average Number of Prescriptions per month for Compounding Orders* (N=164)a

2 (1–4)

Total Number of Years of Providing Compounding (N=220)

10 (4–18)

Reasons for Providing Compounding Services (N = 223)b
Medication is not commercially available

196 (87.9)

Dosage Form not commercially available

51 (22.9)

Needed Dose not commercially available

152 (68.2)

Stability of the desired product

6 (2.7)

Improve adherence to medications

102 (45.7)

Other

1 (0.4)

Reasons for Not Providing Compounding Services (N = 431)b
No prescriptions for compounded preparations

a

232 (53.8)

Compounding require a lot of time (No time)

22 (5.1)

No equipment or/and supplies

105 (24.4)

Pharmacy staff lack skills/training on compounding

15 (3.5)

There are no regulations

9 (2.1)

Lack of trust on compounded medications

23 (5.3)

Compounding of medications is too expensive

14 (3.2)

Compounding of medications is too difficult

32 (7.4)

Compounded medications final cost is too high

11 (2.6)

Others

5 (1.1)

Pharmacies were asked initially about average daily number of prescriptions that contain compounding orders, if not applicable asked about average weekly
number, if not applicable about average monthly number
b
Data do not sum up to 100% as multiple responses/selections were allowed
Abbreviations; IQR Interquartile Range
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Table 3 Comparison of key characteristics of compounding and non-compounding pharmacies
Determinant
Perform Compounding

No (N = 208)

pvalue

3 (13)

20 (87)

0.000*

220 (53.9)

188 (46.1)

Yes (N = 223)
N (%)

Pharmacy Type: Hospital
Community
Chain

69 (60.5)

45 (39.5)

Independent

151 (51.4)

143 (48.6)

0.623*

Mean ±SD
Number of Pharmacists

2.7 ±1.0

2.1 ± 1.8

0.000¥

Number of Assistant

0.64 ± 0.9

0.69 ± 0.9

0.600¥

Number of Personnel

0.7 ± 0.8

0.5 ± 0.7

0.022¥

Average Daily Number of All Received Prescriptions

20 (10-40)#

15 (6-27.8#

0.000¥

p values were calculated using Chi square test
p values were calculated using Mann Whitney test
median (interquartile range)

*

¥
#

pharmacies were more involved in compounding. Pharmacies that prepared compounded medications had significantly higher number of pharmacists and personnel,
and received, on average, a higher number of prescriptions per day.
Factors that showed significant baseline differences between compounding and non-compounding pharmacies
were entered into model testing using logistic regression
to test for significant association with the decision of the
pharmacy to provide compounding service. As shown in
Table 4, the model was significant (OR = 1.47; p = 0.000).
The number of pharmacists (OR = 1.82; p = 0.000), the
number of personnel (OR = 1.09; p = 0.043) and the average number of daily prescriptions received by the pharmacy (OR = 1.02; p = 0.002) were significantly associated
with this service provision. While the type of pharmacy
being hospital or community pharmacy and being part
of a chain or not showed no association with compounding services provision.
Table 5 presents the types of compounded medications and compounding services. Dermatologist were the
main prescriber specialty group requesting compounded
preparations (219, 98.2%). Among the compounded dosage forms, 222 (99.6%) and 204 (91.5%), were creams
and ointments, respectively, and 52 (23.3%) were
Table 4 Analysis of Factors that Affect the Decision of
Pharmacy to Perform Compounding Results Using Stepwise
Logistic Regression Analysis
Determinant

Regression
OR

95% CI

p-value

Model

1.47

Number of Pharmacists

1.82

1.35–2.45

0.000

0.000

Number of Personnel

1.09

0.72–1.65

0.043

Average Daily Number of All Prescriptions

1.02

1.01–1.04

0.002

solutions. Only 5 (2.2%) of the participating pharmacies
that performed compounding prepared sterile products,
with only 3 (1.3%) of compounding pharmacies making
sterile eye drops (Table 5).
About half of pharmacies have mortars, pestles, spatula, and scales, and almost one third of pharmacies have
funnels, flasks, beakers, measuring cylinders, and glass
rods (Table 5).
The main source of references for compounding
protocols were the physician’s order in 210 (94.2%) of
the cases, and protocols developed by the pharmacy
in 100 (44.8%) of the respondent pharmacies. The
main source for estimation of the expiration date for
compounded medications was based on pharmacist’s
experience (129, 57.8%) and physician’s order (119,
53.4%). In 67 (30%) of the compounding pharmacies,
expiration date was not provided for compounded
medications but 217 (97.3%) of these pharmacies attach label to their compounded products. The expiration date included on the label was determined
based on either in-house practice or physician’s order
in 149 (66.8%) and 146 (65.5%) of the compounding
pharmacies, respectively.
In 377 (75.8%) of the compounding pharmacies, no
compounding records were kept, and 34 (63%) of these
records were hand-written. No pharmacy performed
quality control tests of the compounded products.

Discussion
The current study addressed the prevalence, determinants, and characteristics of extemporaneous compounding and compounded products in both
community and hospital pharmacies in Jordan. The
present study is the first report in Jordan and one of few
in the world that present the baseline data on extemporaneous compounding. Several important outcomes that
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Table 5 Compounded Products and Services Provided by
Compounding Pharmacies

Table 5 Compounded Products and Services Provided by
Compounding Pharmacies (Continued)

Parameter

Parameter

Number (%)
a

Specialty of Compounding Prescriber (N = 223)

Number (%)

Published Literature

5 (2.2)

219 (98.2)

USP

9 (4)

Pediatrics

41 (18.4)

BP

25 (11.2)

ENT

24 (10.8)

Self-Reports

100 (44.8)

Gastroenterology

24 (10.8)

Other Pharmacies or Hospitals

11 (4.9)

Radiology

11 (4.9)

Prescriber/Physician

210 (94.2)

Other

37 (16.6)

Dermatology

Provision of Expiration Date on Compounded Medications (N = 431)

Compounded Dosage Forms (N = 223)a
Tablets

0

Capsules

0

Suppository

1 (0.4)

Ointment

204 (91.5)

Cream

222 (99.6)

Solution

52(23.3)

Suspension

10 (4.5)

Syrup

2 (0.9)

Paste

9 (4)

Powder

3 (1.3)

No

No

67 (30)

Published Literature

8 (3.6)

USP

6 (2.7)

BP

16 (7.2)

Self-Reports

129 (57.8)

Other Pharmacies or Hospitals

7 (3.1)

Prescriber/Physician

119 (53.4)

Label Provided on Compounded Medication (N = 223)

5 (2.2)
218 (97.8)

156 (70)

Sources for Estimation of Expiration Date for Compounded Medication
(N = 223)a

Compounded Sterile Products (N = 223)
Yes

Yes

Yes

217 (97.3)

No

6 (2.7)

References for Information Provided on the Label of Compounded
Medication (N = 223)

Types of Compounded Sterile Products (N = 223)

Published Literature

0

Eye Drops

3 (1.3)

USP

36 (16.1)

Electrolytes

1 (0.4)

BP

11 (4.9)

Total Parenteral Nutrition

2 (0.9)

Pharmacist’s Experience

149 (66.8)

Chemotherapy

2 (0.9)

Prescriber/Physician

146 (65.5)

Equipment and Tools Used for Compounding Availability (N = 431)a
Mortars

214 (49.7)

Pestles

213 (49.4)

Capsule Machines

1 (0.2)

Ointment Mill

14 (3.2)

Tablet Machines

0

Suppositories Molds

7 (1.6)

Beaker

131 (30.4)

Funnel

125 (29)

Spatula

213 (49.4)

Scale

188 (43.6)

Flask

118 (27.4)

Water Bath

31 (7.2)

Measuring Cylinder

114 (26.5)

Glass Rod

137 (31.8)

Ointment Slab

60 (13.9)

Sources for protocols of Compounded Medications (N = 223)a

Records for Compounded Medications (N = 431)
Yes

54 (24.2)

No

377 (75.8)

Type of Record/Log-book (N = 54)
Electronic

20 (37)

Hand-written

34 (63)

esting of Quality of Compounded Medications (N = 223) 0
Most Frequently Used Expiration Date, Weeks (N = 223)
a

4 (0.9)

Data do not sum up to 100% as multiple responses/selections were allowed

emerged from this study can be used in the improvement of pharmacy practice.
The high prevalence of the compounding practice in
community pharmacies emphasizes the need of proper
education and training of pharmacy students in extemporaneous compounding. There is also a clear need to
incorporate extemporaneous compounding in professional development and continued education programs
offered by the Jordanian Pharmacy Syndicate and the

AlKhatib et al. BMC Health Services Research

(2019) 19:816

Jordanian Pharmacy Board. Results from this study also
show the critical need for implementation of quality
testing of compounded products and standardized regulations to ensure safe compounding practices.
Data from this study show that 52% of Jordanian pharmacies perform compounding which is less than the percentage (add this percentage) reported in USA [3, 19],
The percentage of prescriptions received per day that
contain at least one compounding order is higher than
those reported in literature [3, 6, 16, 19]. These differences may be attributed to the fact that this study involved all types of Jordanian pharmacies (large and
small, and hospital and community pharmacies).
Buurma and colleagues (2003), reported a decline in
Dutch compounding pharmacies and a rise of specialized
firms that compound and promote those preparations
that are most broadly needed [16].
Several factors can play a role in the pharmacy’s decision to offer compounding services. These factors include the availability of the staff (both pharmacists and
personnel) and the number of all prescriptions received
and filled by the pharmacy. Pharmacies with a higher
number of pharmacists reported making more compounded preparations. The time and efforts required to
develop and manage extemporaneous compounding service are critical factors that influence the prevalence of
compounding in Jordanian pharmacies. This issue has
been addressed in Dutch community pharmacies by preparing a large part of compounded medications from
semi-manufactured or almost finished products provided
by specialized firms. Such products require minimal
work to be finished at the pharmacy [16].
As would be expected, the number of all prescriptions
filled by the pharmacy correlates directly with the compounding services. However, some pharmacies with a
long tradition in providing compounding services were
observed to have a disproportionately higher number of
compounding order to their overall number of prescriptions filled daily.
Dermatologists were reported to be the prescribers of
compounding orders by 98.2% of the compounding
pharmacies in Jordan. They were ahead of other specialties by a large margin. This is in agreement with data
from previously reported study on top indications for
extemporaneously compounded products [16] and could
be related to the observation that creams and ointments
were the most commonly compounded dosage forms by
compounding pharmacies.
The fact that community pharmacies were more involved extemporaneous compounding could be understood in the context that most of the compounded
dosage forms are creams and ointments and the main
prescriber specialty group was “Dermatologists”. Most
health complaints addressed by dermatologists do not
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require hospitalization and prescriptions are often filled
by community rather than hospital pharmacies.
Pediatricians were the second highest specialists in
terms of requesting compounded products with 18.4% of
the compounding pharmacies reporting receiving orders
for compounding from pediatricians. Buurma and colleagues reported that patients less than 12 years old received more extemporaneously prepared medications
than other age groups [16].
Solutions were the third most commonly compounded
dosage form (23.3%) in Jordanian compounding
pharmacies.
Previously reported studies showed that patientcentered pharmaceutical care is the main reason for
pharmacists to provide compounded medications [3, 6].
Pharmaceutical care should address all patients needs by
ensuring the availability of all needed medications, including ingredients combinations, dosage forms, and
doses that are patient-specific. Individualized patient
care results in improved patient’s adherence to medications and consequently better therapeutic outcomes and
quality of life.
As shown in this study, the main reasons for requesting and providing compounding services is the unavailability of the required medications or a specific dosage
form (87.9%) and the unavailability of the required dose
(68.2%). An earlier study has linked the reasons for compounding with the specialty of the prescriber with dermatologists being reported to order combinations that
are usually unavailable commercially and pediatricians
requiring patients-tailored dosage strengths [16].
The majority of pharmacies participating in this study
stated lack of prescriptions for extemporaneously compounded products as a key reason for not providing
compounding services. Zaid et al. [6] and McPherson
et al. [3] also reported that that the main reason for
pharmacists being non-compounders is not receiving
prescriptions. Surprisingly, the second reported reason
for not compounding was the lack of equipment and
supplies. This is unexpected because by the law, each licensed pharmacy is required to have compounding tools
and equipment. Interestingly, required time, cost, and
difficulty of preparing these medications did not have
impact on the pharmacy’s decision to provide compounding services.
In general, sterile compounding was not performed in
pharmacies participating in this study. This can be explained by the fact that compounding of sterile products
is expensive because it requires sterile environment, specific procedures and equipment. Improper preparation
of sterile compounded preparations may easily lead to
contaminated product [6].
Buurma and colleagues reported that in 42% of the
cases, pharmacies did not use a standardized or semi-
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standardized protocol [16]. The current study showed
the lack of standardized procedures for compounding
with vast majority of the respondents stating that the
physician order is the source of the procedure while
44.8% reported the use of procedures developed in the
pharmacy for compounding different products. The
same resources were reported to be relied upon for estimation of expiration date for compounded medicines
and labeling of the compounded products.
Moreover, the study uncovers the lack of documentation and quality assurance of the compounded product,
although 24.2% of pharmacies keep records for their
products and considerable number of pharmacists seeks
patients’ feedback on their products. Despite of all of
this, there is a need for agreed on protocols that cover
procedures, labelling including expiry date, and quality
control tests that should be followed and guaranteed
during extemporaneous compounding to assure effectiveness and quality of the final product and improve the
physicians as well as patients’ confidence in these
products.
The main limitation of this study is the difference in
the number of community (408) and hospital pharmacies (23) included in the study. However, it is worth noting that we tried to include a similar proportion of
community (18.1%) and hospital (21.7%) pharmacies of
all those operating in Jordan. Another limitation is the
fact that this study did not cover the compounding practice from the perspective of prescribers and patients.
This includes the study of drivers for prescribing compounded products and the patients’ experience with the
compounding services offered by pharmacies. We are
attempting to cover this aspect in a future study.
The data presented in this study was presented to and
discussed with faculty members at the School of Pharmacy, University of Jordan in order to modify curriculum to better cover procedures, labelling including
expiry date, and quality control tests that should be
followed and guaranteed during extemporaneous compounding to assure effectiveness and quality of the final
product and improve the physicians as well as patients’
confidence in these products. In addition, a plan was developed for offering a continuing education program to
practicing pharmacists in collaboration with the Jordanian Pharmacists Syndicate in the area of best practices in
extemporaneous compounding.

significantly associated with a higher number of extemporaneous products compounded. The lack of standardized procedures for preparing extemporaneous products,
scientific basis for determination of expiration date of
compounded products, and lack of quality control testing prompts an action.

Conclusion
Extemporaneous compounding is a widely spread
pharmaceutical practice among community pharmacies
in Jordan. Ointments and creams are the most commonly prescribed and compounded extemporaneous
products. A higher number of pharmacists, pharmacy
personnel and the total number of prescriptions were
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